Researchers develop sequencing platform that generates "clinical-grade" data from small amounts of tumor sample DNA

May 19, 2014 by Bob Yirka, Medical Xpress report
genome

(Medical Xpress)—A large team of researchers with members from several universities and hospitals in the U.S. has developed a sequencing platform that generates "clinical-grade" data using whole exome sequencing (WES) from small amounts of DNA extracted from clinical tumor samples. In their paper published in the journal Nature Medicine, the team describes their new method and how it might soon be used in routine clinical practice.

Over the past several years scientists have learned that different types of cancers with different types of associated tumors can be genetically different from one another and that the different types respond differently to different . Because matching the type of treatment options to tumor types is still so new, researchers are still working out the best ways to go about doing so. Quite often, small samples of tumors are taken which are then genetically tested to see if the genome, or parts of it match known conditions that have been successfully treated using a certain therapy. More recently, it's become clear that WES offers a better approach, it allows for sequencing the whole genome rather than just a part of it. Efforts to do so have, however, been held back by the lack of a method to perform such sequencing on tumor samples stored using fixed in formalin and embedded in paraffin (FFEP), the standard method used to store such samples—it tends to degrade genetic material. In this new effort the researchers came up with a way to use such samples to perform WES.

The breakthrough was the development of an algorithm that is run on a computer that analyses the results of WES—they've named it precision heuristics for interpreting the alteration landscape (PHIAL). It collects genetic data and then sorts it by variation based on already known information about such variations and treatment options for them. It finishes by noting what has been found regarding the genome and by noting treatment options that have been the most successful at treating tumors with similar variations.

The researchers tested their system on 511 actual patients and found it was able to pick out 1,842 alterations out of 250,000 variants for which there are known treatment options. They also found that the system was able to identify clinically relevant alterations in 15 of 16 patients, one of whom was a lung cancer patient who responded positively to a particular therapy after being guided there by the system.

The researchers note that their system allows for expanding the WES knowledgebase—data from their system can be added to an ever increasing database, providing the algorithm ever more information to use in sorting.

Explore further: Fast, simple-to-use assay reveals the 'family tree' of cancer metastases

More information: (Medical Xpress)—Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine, Nature Medicine (2014) DOI: 10.1038/nm.3559

Abstract
Translating whole-exome sequencing (WES) for prospective clinical use may have an impact on the care of patients with cancer; however, multiple innovations are necessary for clinical implementation. These include rapid and robust WES of DNA derived from formalin-fixed, paraffin-embedded tumor tissue, analytical output similar to data from frozen samples and clinical interpretation of WES data for prospective use. Here, we describe a prospective clinical WES platform for archival formalin-fixed, paraffin-embedded tumor samples. The platform employs computational methods for effective clinical analysis and interpretation of WES data. When applied retrospectively to 511 exomes, the interpretative framework revealed a 'long tail' of somatic alterations in clinically important genes. Prospective application of this approach identified clinically relevant alterations in 15 out of 16 patients. In one patient, previously undetected findings guided clinical trial enrollment, leading to an objective clinical response. Overall, this methodology may inform the widespread implementation of precision cancer medicine.

Related Stories

Fast, simple-to-use assay reveals the 'family tree' of cancer metastases

April 21, 2014
A Massachusetts General Hospital-based research team has developed a simple assay that can reveal the evolutionary relationships between primary tumors and metastases within a patient, information that may someday help with ...

Next-generation sequencing test identified potential targets for pediatric cancer treatments

November 5, 2013
A comprehensive genomic profiling test using next-generation sequencing has identified genomic alterations in more than half of pediatric cancer samples tested that would give clinicians potential targets on which to base ...

Immunogenic mutations in tumor genomes correlate with increased patient survival

April 29, 2014
Developing immunotherapies for cancer is challenging because of significant variability among tumors and diversity in human immune types. In a study published online today in Genome Research, researchers examined the largest ...

Tumor suppressor gene TP53 mutated in 90 percent of most common childhood bone tumor

April 3, 2014
The St. Jude Children's Research Hospital—Washington University Pediatric Cancer Genome Project found mutations in the tumor suppressor gene TP53 in 90 percent of osteosarcomas, suggesting the alteration plays a key role ...

Scientists identify genetic blueprint for cancerous tumors of the appendix

May 12, 2014
Using next generation DNA sequencing, Dartmouth scientists have identified potentially actionable mutations in cancers of the appendix. Their study, "Molecular Profiling of Appendiceal Epithelial Tumors Using Massively Parallel ...

First large-scale study of whole-genome testing helps identify best treatment for women with advanced breast cancer

February 6, 2014
The first large-scale study testing all the DNA—the entire genome—of tumor cells from more than 400 women with advanced breast cancer has identified individuals with a good chance of benefiting from specific treatments ...

Recommended for you

Psychiatric disorders share an underlying genetic basis

June 21, 2018
Psychiatric disorders such as schizophrenia and bipolar disorder often run in families. In a new international collaboration, researchers explored the genetic connections between these and other disorders of the brain at ...

Deep data dive helps predict cerebral palsy

June 21, 2018
When University of Delaware molecular biologist Adam Marsh was studying the DNA of worms living in Antarctica's frigid seas to understand how the organisms managed to survive—and thrive—in the extremely harsh polar environment, ...

Genetic variation in progesterone receptor tied to prematurity risk, study finds

June 21, 2018
Humans have unexpectedly high genetic variation in the receptor for a key pregnancy-maintaining hormone, according to research led by scientists at the Stanford University School of Medicine. The finding may help explain ...

Shared genetics may shape treatment options for certain brain disorders

June 20, 2018
Symptoms of schizophrenia and bipolar disorder, including psychosis, depression and manic behavior, have both shared and distinguishing genetic factors, an international consortium led by researchers from Vanderbilt University ...

Scientists unravel DNA code behind rare neurologic disease

June 20, 2018
Scientists conducting one of the largest full DNA analyses of a rare disease have identified a gene mutation associated with a perplexing brain condition that blinds and paralyzes patients.

Simple sugar delays neurodegeneration caused by enzyme deficiency

June 20, 2018
A new therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB). Neurodegeneration in this condition results from the abnormal accumulation of essential cellular ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Scottingham
not rated yet May 19, 2014
This technology combined with IBM's Watson is really going to shake things up.

"With that tumor type we suspect it will respond to drug X because it has the same receptor expression of known types A, B and D which are known to respond to drug X."

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.